Sermorelin dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg compounded vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 300 mcg dose equals 12 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical Sermorelin dose is 0.3 mg (Adult compounded: 200 to 500 mcg daily SC pre-bed, or 200 to 300 mcg twice daily. Pediatric label was 0.03 mg/kg daily.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 1-2x daily. Half-life of 0.25 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Historical pediatric GHD use was continuous over 6 to 12 months. Adult anecdotal protocols often run 8 to 12 weeks on, 4 weeks off.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: injection-site pain or irritation; transient flushing; headache; vivid dreams (pre-bed dosing). Stop or reduce dose if tolerability breaks down.

Why this dose

Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop.

The typical dose (0.3 mg) reflects Adult compounded: 200 to 500 mcg daily SC pre-bed, or 200 to 300 mcg twice daily. Pediatric label was 0.03 mg/kg daily.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Sermorelin is administered via the subcutaneous route. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 15 minutes after administration. Peak effect lands near 30 minutes post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: ~10 to 20 minute plasma half-life produces a discrete pulsatile GH release closer to physiology than continuous rhGH or DAC-tethered GHRH analogs.

Cycling and tolerance

Historical pediatric GHD use was continuous over 6 to 12 months. Adult anecdotal protocols often run 8 to 12 weeks on, 4 weeks off.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
• Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
• Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
• Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
• Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
• Banned by WADA under S2 (peptide hormones, growth factors)

Side effects and interactions

Common side effects

• injection-site pain or irritation
• transient flushing
• headache
• vivid dreams (pre-bed dosing)

Notable interactions

• insulin (moderate): sustained GH can blunt insulin sensitivity over weeks
• corticosteroids (moderate): blunt GH response; reduce expected efficacy
• levothyroxine (untreated hypothyroidism) (moderate): untreated hypothyroidism blunts GH response; correct thyroid first
• ipamorelin (minor): synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing
• CJC-1295 (minor): pharmacologically redundant (both GHRH-pathway); typically not stacked

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Sermorelin profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Rx only via compounding (no controlled-substance schedule)

Pregnancy

Category C (historical labeling); not recommended in pregnancy

Legal status

FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA

Do not use if

• pregnancy
• active malignancy
• history of pituitary tumor
• diabetic retinopathy (theoretical)
• untreated hypothyroidism

Related research